AMYLOID-TARGETED THERAPEUTICS IN ALZHEIMER'S DISEASE: USE OF HUMAN ALBUMIN IN PLASMA EXCHANGE AS A NOVEL APPROACH FOR Aβ MOBILIZATION
AMYLOID-TARGETED THERAPEUTICS IN ALZHEIMER'S DISEASE: USE OF HUMAN ALBUMIN IN PLASMA EXCHANGE AS A NOVEL APPROACH FOR Aβ MOBILIZATION
复制标题
DOI：
10.1358/dnp.2009.22.6.1395256
复制
发表时间：
2009-07-01
影响因子：
--
通讯作者：
Paez, Antonio
中科院分区：
文献类型：
--
作者：
Boada, Merce;Ortiz, Pilar;Paez, Antonio
一个临床。进行了一项研究计划，通过血浆交换（PE）计划，用5%人白蛋白Grifols（R）替代轻度至中度阿尔茨海默病（AD）患者的内源性白蛋白，以改变白蛋白结合A β之间的动态平衡血浆中的A β和脑脊髓液中的A β。在一项初步概念验证研究中，7例患者在3周和1年随访期内接受了6次PE。血浆A β测定结果显示与PE相关的水平变化模式。认知状态评分（MMSE和ADAS-Cog）比预期更稳定。在一项II期临床试验中，29例患者随机分为PE治疗组和对照组，随访1年。中期结果表明，PE治疗的患者发生了A β（40）动员，这些患者在认知测试中得分更高（9个月时的差异：MMSE为2.5，ADAS-cog为5.5）。这些结果表明，5%人血白蛋白Grifols的PE方案在治疗轻度至中度AD中可能具有良好的作用。
A clinical. investigation program was carried out to replace endogenous albumin of patients with mild to moderate Alzheimer's disease (AD) with 5% Human Albumin Grifols (R) through a plasma exchange (PE) schedule, in order to alter the dynamic equilibrium between albumin-bound A beta in plasma and A beta in cerebrospinal, fluid. In a pilot proof-of-concept study, 7 patients underwent 6 PE in 3 weeks and 1 year of follow-up. Plasma A beta determinations demonstrated a variation pattern in levels in relation with the PEs. Cognitive status scores (MMSE and ADAS-Cog) were more stable than expected. In a phase II clinical trial, 29 patients were randomized into PE-treated and control groups with 1 year follow-up. Interim results point toward the occurrence of A beta(40) mobilization in the PE-treated patients, who scored better in cognitive tests (differences at 9 months: 2.5 in MMSE and 5.5 in ADAS-cog). These results suggest that a PE program with 5% Human Albumin Grifols may have a promising role in the treatment of mild to moderate AD.